Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma

Imagem de Miniatura
Arquivos
art_ARRUDA_Consensus_of_the_Brazilian_Society_of_Infectious_Diseases_2014.PDF (293.47 KB)
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2014
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CONTEXTO
Autores
ARRUDA, Erico
JACOME, Alexandre Andrade dos Anjos
TOSCANO, Ana Luiza de Castro Conde
SILVESTRINI, Anderson Arantes
REGO, Andre Santa Barbara
WIERMANN, Evanius Garcia
CUNHA JR., Geraldo Felicio da
MELO, Heloisa Ramos Lacerda de
MOREJON, Karen Mirna Loro
GOLDANI, Luciano Zubaran
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.18, n.3, p.315-326, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Kaposi's sarcoma is a multifocal vascular lesion of low-grade potential that is most often present in mucocutaneous sites and usually also affects lymph nodes and visceral organs. The condition may manifest through purplish lesions, flat or raised with an irregular shape, gastrointestinal bleeding due to lesions located in the digestive system, and dyspnea and hemoptysis associated with pulmonary lesions. In the early 1980s, the appearance of several cases of Kaposi's sarcoma in homosexual men was the first alarm about a newly identified epidemic, acquired immunodeficiency syndrome. In 1994, it was finally demonstrated that the presence of a herpes virus associated with Kaposi's sarcoma called HHV-8 or Kaposi's sarcoma herpes virus and its genetic sequence was rapidly deciphered. The prevalence of this virus is very high (about 50%) in some African populations, but stands between 2% and 8% for the entire world population. Kaposi's sarcoma only develops when the immune system is depressed, as in acquired immunodeficiency syndrome, which appears to be associated with a specific variant of the Kaposi's sarcoma herpes virus. There are no treatment guidelines for Kaposi's sarcoma established in Brazil, and thus the Brazilian Society of Clinical Oncology and the Brazilian Society of Infectious Diseases developed the treatment consensus presented here.
Palavras-chave
Kaposi's sarcoma, AIDS, Consensus, Cutaneous
URI
https://observatorio.fm.usp.br/handle/OPI/7766
Referências
  1. [Anonymous], 1981, MMWR MORB MORTAL WKL, V30, P305
  2. Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407
  3. Bodsworth N J, 2001, Am J Clin Dermatol, V2, P77, DOI 10.2165/00128071-200102020-00004
  4. Bower M, 2008, HIV MED, V9, P336, DOI 10.1111/j.1468-1293.2008.00608.x
  5. Bower M, 2005, J CLIN ONCOL, V23, P5224, DOI 10.1200/JCO.2005.14.597
  6. Cattelan AM, 2001, J NATL CANC I MONOGR, V28, P44
  7. Chan J, 1999, J ACQ IMMUN DEF SYND, V22, P209
  8. CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
  9. Cheung TW, 2004, CANCER INVEST, V22, P774, DOI 10.1081/CNV-200032788
  10. Cianfrocca M, 2010, CANCER-AM CANCER SOC, V116, P3969, DOI 10.1002/cncr.25362
  11. Cooley T, 2007, ONCOLOGIST, V12, P114, DOI 10.1634/theoncologist.12-1-114
  12. COOPER JS, 1991, INT J RADIAT ONCOL, V20, P419
  13. Dezube BJ, 1996, HEMATOL ONCOL CLIN N, V10, P1023, DOI 10.1016/S0889-8588(05)70382-8
  14. Engels EA, 2003, AIDS, V17, P1847, DOI 10.1097/01.aids.0000076275.54156.08
  15. EPSTEIN JB, 1989, CANCER, V64, P2424, DOI 10.1002/1097-0142(19891215)64:12<2424::AID-CNCR2820641205>3.0.CO;2-X
  16. FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3
  17. Gallafent JH, 2005, J CLIN ONCOL, V23, P1253, DOI 10.1200/JCO.2005.04.156
  18. Gill J, 2002, JAIDS-J ACQ IMM DEF, V31, P384
  19. Gill PS, 1999, J CLIN ONCOL, V17, P1876
  20. Gill PS, 1996, J CLIN ONCOL, V14, P2353
  21. GILL PS, 1989, ANN INTERN MED, V110, P937
  22. GILL PS, 1989, AM J MED, V87, P57
  23. Grabar S, 2006, J CLIN ONCOL, V24, P3408, DOI 10.1200/JCO.2005.05.4072
  24. GROOPMAN JE, 1984, ANN INTERN MED, V100, P671
  25. GUO WX, 1995, AM J PATHOL, V146, P727
  26. Henry D, 2002, P AN M AM SOC CLIN, V21, p411a
  27. Holkova B, 2001, J CLIN ONCOL, V19, P3848
  28. Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823
  29. Janusch M, 2006, EUR J DERMATOL, V16, P494, DOI 10.1684/ejd.2006.0041
  30. Kedes DH, 1997, J CLIN INVEST, V99, P2082, DOI 10.1172/JCI119380
  31. KRIGEL RL, 1983, CANCER TREAT REP, V67, P531
  32. Krown SE, 2008, NEW ENGL J MED, V358, P535, DOI 10.1056/NEJMc072994
  33. Krown SE, 1997, J CLIN ONCOL, V15, P3085
  34. Krown SE, 2004, J CLIN ONCOL, V22, P399, DOI 10.1200/JCO.2004.08.064
  35. KROWN SE, 1989, J CLIN ONCOL, V7, P1201
  36. Ledergerber B, 1999, BRIT MED J, V319, P23
  37. Lee PC, 1996, HEMATOL ONCOL CLIN N, V10, P1051
  38. Leidner RS, 2005, AIDS PATIENT CARE ST, V19, P635, DOI 10.1089/apc.2005.19.635
  39. lexner C, 1998, NEW ENGL J MED, V338, P1281
  40. Little RF, 2006, BLOOD, V107, P4650, DOI 10.1182/blood-2005-11-4455
  41. Lodi S, 2010, J NATL CANCER I, V102, P784, DOI 10.1093/jnci/djq134
  42. Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402
  43. Martin-Carbonero L, 2004, AIDS, V18, P1737, DOI 10.1097/01.aids.0000131385.60974.b9
  44. Martinez V, 2006, BRIT J CANCER, V94, P1000, DOI 10.1038/sj.bjc.6603056
  45. Medveczky MM, 1997, AIDS, V11, P1327, DOI 10.1097/00002030-199711000-00006
  46. Minsiterio da Saude Protocolo Clinic e Diretrizes, 2013, TER AD VIV COM HIV A
  47. MITSUYASU RT, 1987, SEMIN ONCOL, V14, P13
  48. Mosam A, 2012, JAIDS-J ACQ IMM DEF, V60, P150, DOI 10.1097/QAI.0b013e318251aedd
  49. Nasti G, 2003, J CLIN ONCOL, V21, P2876, DOI 10.1200/JCO.2003.10.162
  50. National Comprehensive Cancer Network, 2013, NCCN CLIN PRACT GUID
  51. Nguyen HQ, 2008, AIDS, V22, P937, DOI 10.1097/QAD.0b013e3282ff6275
  52. NOBLER MP, 1987, J CLIN ONCOL, V5, P107
  53. Northfelt DW, 1998, J CLIN ONCOL, V16, P2445
  54. Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
  55. Pantanowitz L, 2004, AIDS READ, V14, P251
  56. Dezube Bruce J, 2004, AIDS Read, V14, P236
  57. Pantanowitz L, 2004, J CUTAN PATHOL, V31, P26, DOI 10.1046/j.0303-6987.2004.0132.x
  58. Pantanowitz L, 2004, AIDS READ, V14, P243
  59. Pantanowitz L, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-190
  60. PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003
  61. Portsmouth S, 2003, AIDS, V17, pF17, DOI 10.1097/01.aids.0000076309.76477.f1
  62. REAL FX, 1986, J CLIN ONCOL, V4, P544
  63. Regnier-Rosencher E, 2013, J AM ACAD DERMATOL, V68, P313, DOI 10.1016/j.jaad.2012.04.018
  64. SELIK RM, 1987, AIDS, V1, P175
  65. Sgadari C, 2002, NAT MED, V8, P225, DOI 10.1038/nm0302-225
  66. Singh NB, 2008, RADIOTHER ONCOL, V88, P211, DOI 10.1016/j.radonc.2008.03.009
  67. Stebbing J, 2006, LANCET, V367, P1495, DOI 10.1016/S0140-6736(06)68649-2
  68. Stewart S, 1998, J CLIN ONCOL, V16, P683
  69. TAYLOR JF, 1971, INT J CANCER, V8, P122, DOI 10.1002/ijc.2910080116
  70. TEMPLETON AC, 1975, J NATL CANCER I, V55, P1301
  71. Tiussi RM, 2012, AN BRAS DERMATOL, V87, P220, DOI 10.1590/S0365-05962012000200005
  72. Tulpule A, 2002, CANCER, V95, P147, DOI 10.1002/cncr.10634
  73. Velho Paulo Eduardo Neves Ferreira, 2003, An. Bras. Dermatol., V78, P601, DOI 10.1590/S0365-05962003000500010
  74. VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0
  75. Wang T, 2013, J ONCOPATHOL, V00, p:1
  76. Welles L, 1998, J CLIN ONCOL, V16, P1112

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03